Ori Gutwerg Sells 2,060 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Ori Gutwerg sold 2,060 shares of ANI Pharmaceuticals stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $76.50, for a total transaction of $157,590.00. Following the sale, the senior vice president owned 84,782 shares in the company, valued at $6,485,823. This represents a 2.37% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

ANI Pharmaceuticals Price Performance

Shares of ANIP stock opened at $75.60 on Friday. The firm has a fifty day simple moving average of $79.83 and a 200-day simple moving average of $86.04. The company has a market capitalization of $1.70 billion, a PE ratio of 22.50 and a beta of 0.52. ANI Pharmaceuticals, Inc. has a twelve month low of $56.71 and a twelve month high of $99.50. The company has a current ratio of 2.71, a quick ratio of 2.19 and a debt-to-equity ratio of 1.11.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. raised its position in shares of ANI Pharmaceuticals by 2.2% during the 4th quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock valued at $103,022,000 after acquiring an additional 27,598 shares in the last quarter. Global Alpha Capital Management Ltd. increased its stake in ANI Pharmaceuticals by 17.2% during the second quarter. Global Alpha Capital Management Ltd. now owns 862,090 shares of the specialty pharmaceutical company’s stock valued at $56,251,000 after purchasing an additional 126,500 shares during the last quarter. State Street Corp raised its holdings in shares of ANI Pharmaceuticals by 2.2% during the fourth quarter. State Street Corp now owns 727,204 shares of the specialty pharmaceutical company’s stock worth $57,405,000 after purchasing an additional 15,496 shares during the period. UBS Group AG lifted its position in shares of ANI Pharmaceuticals by 45.8% in the 3rd quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock worth $54,032,000 after buying an additional 185,172 shares during the last quarter. Finally, Tang Capital Management LLC lifted its position in shares of ANI Pharmaceuticals by 51.6% in the 4th quarter. Tang Capital Management LLC now owns 481,437 shares of the specialty pharmaceutical company’s stock worth $38,005,000 after buying an additional 163,937 shares during the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

Key ANI Pharmaceuticals News

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: Analyst support remains strong — Guggenheim has reiterated/maintained a buy stance and has previously raised its target (recent coverage keeps favorable analyst attention, supporting longer-term demand). Guggenheim Sticks to Their Buy Rating for ANI Pharmaceuticals (ANIP)
• Positive Sentiment: Reported insider buy: a Benzinga item flags an SVP & CFO purchase of roughly $1.7M of ANIP stock — insider buying can be a positive signal about management’s view of valuation. SVP & CFO At ANI Pharmaceuticals Buys $1.72M of Stock
• Neutral Sentiment: Short interest readings in recent reports show 0 shares (figures include NaN/inconsistent values and days-to-cover of 0.0), suggesting reporting oddities rather than a meaningful short-squeeze risk at present.
• Negative Sentiment: Material insider selling by the CFO — Stephen P. Carey sold 7,312 shares at an average of $75.50 (disclosed via SEC filing). While the CFO still holds a large stake, the sale reduces insider position and can pressure sentiment. CFO Form 4 (SEC)
• Negative Sentiment: Other insider sales: SVP Ori Gutwerg sold 2,060 shares at ~$76.50 (SEC filing) and insider Christopher Mutz sold 417 shares at $74 (plus a prior sale of 5,323 shares on Feb 20). Multiple near-term insider sales can weigh on near-term sentiment. Ori Gutwerg Form 4 (SEC) InsiderTrades: Christopher Mutz sale

Analyst Upgrades and Downgrades

ANIP has been the topic of a number of analyst reports. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research report on Monday, December 29th. Barclays assumed coverage on ANI Pharmaceuticals in a report on Tuesday, December 9th. They set an “overweight” rating and a $100.00 price objective on the stock. Zacks Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. Finally, Guggenheim lifted their price target on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. Six investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, ANI Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $103.43.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.